Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 HR and 95% CI for the associations between risk factors and 5-year recurrence by tumor molecular subtype

From: Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population

Risk factora Recurrence after 5 years P-hetd
A-like B-like HER2-enriched Triple-negative
N/events HR (95% CI) N/events HR (95% CI) N/events HR (95% CI) N/events HR (95% CI)
Ethnicity
 Chinese 567/34 1.00 (reference) 435/49 1.00 (reference) 180/30 1.00 (reference) 275/38 1.00 (reference) 0.96
 Malay 204/8 1.01 (0.39, 2.60) 263/30 0.81 (0.45, 1.45) 104/17 0.69 (0.31, 1.51) 155/24 1.11 (0.61, 2.02)  
 Native 245/16 1.17 (0.49, 2.79) 291/22 0.84 (0.46, 1.55) 103/10 0.47 (0.18, 1.23) 190/22 0.67 (0.34, 1.34)  
P value   0.75   0.55   0.11   0.32  
Menarche
  ≤ 12 yrs 344/13 1.00 (reference) 326/38 1.00 (reference) 118/14 1.00 (reference) 190/34 1.00 (reference) 0.07
 13 yrs 318/17 1.55 (0.57, 4.23) 340/31 1.03 (0.58, 1.82) 148/21 1.52 (0.69, 3.33) 201/24 0.72 (0.38, 1.37)  
 14 yrs 163/14 2.51 (0.86, 7.33) 167/21 0.81 (0.40, 1.64) 60/9 0.56 (0.16, 1.92) 111/13 0.65 (0.30, 1.43)  
  ≥ 15 yrs 184/13 3.26 (1.08, 9.92) 148/11 0.77 (0.35, 1.68) 57/12 1.11 (0.38, 3.28) 113/12 0.61 (0.27, 1.36)  
P value   0.02   0.41   0.81   0.18  
Parity and BFc
 Nulliparous 242/19 1.00 (reference) 224/16 1.00 (reference) 77/12 1.00 (reference) 128/19 1.00 (reference) 0.56
 Parous and No BF 133/7 0.55 (0.20, 1.50) 103/14 1.86 (0.76, 4.56) 31/7 1.35 (0.39, 4.64) 64/17 1.57 (0.67, 3.66)  
 Parous and BF 641/32 0.27 (0.12, 0.58) 662/71 1.63 (0.81, 3.28) 279/38 0.58 (0.25, 1.34) 428/48 0.77 (0.39, 1.52)  
P value   0.001   0.23   0.15   0.28  
Age at FFPd
  < 25 400/13 1.00 (reference) 445/44 1.00 (reference) 183/30 1.00 (reference) 294/41 1.00 (reference) 0.52
  ≥ 25 374/26 1.69 (0.66, 4.34) 320/41 1.32 (0.78, 2.22) 127/15 0.50 (0.21, 1.16) 197/23 0.75 (0.41, 1.39)  
P value   0.27   0.28   0.10   0.36  
Family history
 No 840/42 1.00 (reference) 854/85 1.00 (reference) 338/49 1.00 (reference) 516/66 1.00 (reference) 0.94
 Yes 160/13 0.77 (0.29, 2.03) 119/14 1.17 (0.60, 2.28) 46/7 1.24 (0.45, 3.35) 92/12 0.85 (0.43, 1.70)  
P value   0.60   0.64   0.67    
BMI, kg/m2
 18.5–24.9 160/6 1.00 (referent) 172/14 1.00 (referent) 68/11 1.00 (referent) 114/16 1.00 (referent) 0.98
  < 18.5 373/30 3.97 (0.91, 17.34) 336/29 1.37 (0.62, 3.03) 163/21 0.50 (0.20, 1.27) 240/30 1.01 (0.51, 2.01)  
P value   0.06   0.43   0.15   0.97  
 25–30 317/16 3.40 (0.75, 15.42) 301/37 2.02 (0.95, 4.29) 104/15 0.70 (0.27, 1.81) 177/24 0.83 (0.39, 1.73)  
P value   0.11   0.06   0.46   0.62  
  > 30 136/5 1.65 (0.27, 10.15) 148/15 1.28 (0.53, 3.12) 38/7 1.41 (0.46, 4.27) 66/13 0.89 (0.35, 2.25)  
P value   0.59   0.58   0.55   0.81  
  1. In bold are variables which met our criteria (P-value < 0.1) for inclusion in multivariate models
  2. aEach risk factor was adjusted for age, ethnicity, BMI, tumor stage, histologic grade, surgery, systemic therapy (endocrine (tamoxifen or AI versus none), chemotherapy (any regimen versus none)) and radiotherapy (received versus none)
  3. bBF breastfeeding
  4. cFFP first full-term pregnancy. Due to sample size considerations age at FFP was dichotomized
  5. dP value for heterogeneity (P-het) of HR estimates according to molecular subtypes